$10 Billion Deal, page-12563

First 12563 Last

Share
Profile

Follow
fishman67

4,228 Posts.

667

17/05/24

15:39

Post #: 73881834
Share
Originally posted by Fingers xed ↑

My mate Bard again Fish :
Biotronhave a human trial design which has been completed that is testing its compoundBIT225 on HIV patients that are on art , and have undetectable levels of HIV .How do you see that they may be able to get any result or proof that theircompound will work ?
Testing BIT225 on HIV patients withundetectable viral loads presents a challenge in demonstrating the drug'seffectiveness against HIV. Here's why:

Undetectable viral load: The primary measure of successful HIV treatment is an undetectable viral load. This means there are not enough copies of the virus in the blood to be measured by standard tests. Therefore, simply measuring viral load wouldn't show a change with BIT225, as the viral load is already undetectable.

Here are some alternative approaches Biotroncould consider to assess the efficacy of BIT225 in this patient population:

Viral Reservoir Assay: This assay attempts to measure the size of the HIV reservoir, which is the hidden pool of infected cells that harbor latent HIV. If BIT225 is effective in reducing the reservoir size, it could be considered a positive outcome, even if the viral load remains undetectable.

Immune Response Markers: Measuring changes in specific immune cells or immune system activity could be an indicator of BIT225's effect on HIV. An increase in immune function could suggest the drug is helping the body control the virus.

Analytical Treatment Interruption (ATI): This is a more complex approach. Patients would stop taking their current antiretroviral therapy (ART) for a short, controlled period. If BIT225 is effective in suppressing the virus, it might delay the rebound of detectable HIV viral load after stopping ART compared to a placebo group. However, this approach carries ethical considerations and potential health risks for participants.

Pre-Exposure Prophylaxis (PrEP) Trial: Biotron could consider testing BIT225 in a different population - HIV-negative individuals at high risk of acquiring HIV. Here, the drug's effectiveness could be measured by its ability to prevent HIV infection altogether.

Mathematical Modeling: Mathematical models can be used to analyze existing data on HIV and the mechanisms of action of BIT225. This might help predict the drug's potential impact on the viral reservoir or other aspects of HIV infection.

It's important to note that even with thesealternative approaches, definitively proving BIT225's ability to eradicate orcure HIV would be challenging. However, these methods could provide valuabledata on the drug's potential impact on the virus and the immune system.
Ultimately, the best approach for Biotronwould depend on the specific goals of the trial and the resources available.Consulting with HIV/AIDS experts and regulatory bodies would be crucial indesigning a scientifically sound and ethically responsible clinical trial.

Expand

Nice work Fingers……..Definitely not a simple process by any means, this is it Fingers this is where the industry is at companies across the world are now working on trying to clear the virus from the latent Reservoir. A positive outcome will seal the deal…….
BIT Price at posting: 5.5¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

AR3

Overland drilling proves promising for Australian Rare Earths' uranium hopes

CPV

ClearVue inks deal with UK heated glass player to combine solar tech with its offering

There are more pages in this discussion • 824 more messages in this thread...

First 12563 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 2.0¢		Change 0.001(2.63%)		Mkt cap ! $17.59M

Open	High	Low	Value	Volume
2.0¢	2.0¢	2.0¢	$2.95K	150.0K

Buyers (Bids)

No.	Vol.	Price($)
9	1639605	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	229686	3

View Market Depth

No.	Vol.	Price($)
9	1639605	0.019
11	2301165	0.018
5	688000	0.017
10	1492350	0.016
5	760000	0.015

Price($)	Vol.	No.
0.020	229686	3
0.021	188000	3
0.022	600000	2
0.023	323000	3
0.024	255035	3

Last trade - 10.58am 13/11/2024 (20 minute delay)

BIT (ASX) Chart

$10 Billion Deal, page-12563

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

Overland drilling proves promising for Australian Rare Earths' uranium hopes

ClearVue inks deal with UK heated glass player to combine solar tech with its offering

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

$10 Billion Deal, page-12563

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

Overland drilling proves promising for Australian Rare Earths' uranium hopes

ClearVue inks deal with UK heated glass player to combine solar tech with its offering

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News